INTEGRAL MOLECULAR INC — Department of Health and Human Services SBIR Phase II: 100

Description

DESCRIPTION provided by applicant Acute and chronic pain resulting from injury surgery or disease afflicts andgt million Americans each year having a severe impact on mood mental health and quality of life and costing the U S approximately $ billion in economic costs annually For many patients treatment options provide inadequate relief because of the shortcomings of available therapeutics To date most treatments for pain have been small molecule compounds that block the activity of select ion channels or other pain receptors but these therapeutics often result in side effects caused by off target binding or suffer from poor bioavailability These limitations have prompted renewed searches for novel targets for the treatment of pain and novel types of inhibitors capable of achieving the specificity and bioavailability needed for a successful therapeutic The P X ion channel is a primary mediator of pain triggered by ATP release and drugs that target P X could be efficacious in treating chronic pain Here we propose to develop MAbs targeting the ion channel P X for the treatment of neuropathic and inflammatory pain PUBLIC HEALTH RELEVANCE This proposal will contribute to public health and the cure of human disease by resulting in the development of therapeutic MAbs against P X to treat neuropathic and inflammatory pain Lead MAbs with confirmed specificity and efficacy will be developed with the goal of entering pre clinical studies and the filing of an IND for studies in humans